Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 12Gastrointestinal 5NET 3Genitourinary 3Dermatologic 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × pasireotide × Head & Neck × Clear all
NCT01270321 2021-02-17

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Emory University

Phase 2 Completed
42 enrolled 11 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡